BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther. 2016;43:317-333. [PMID: 26607562 DOI: 10.1111/apt.13475] [Cited by in Crossref: 193] [Cited by in F6Publishing: 169] [Article Influence: 27.6] [Reference Citation Analysis]
Number Citing Articles
1 Al-bawardy B, Hansel SL, Fidler JL, Barlow JM, Bruining DH. Endoscopic and Radiographic Assessment of Crohn's Disease. Gastroenterology Clinics of North America 2017;46:493-513. [DOI: 10.1016/j.gtc.2017.05.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
2 Beilman CL, Kirwin E, Ma C, Mccabe C, Fedorak RN, Halloran B. Early Initiation of Tumor Necrosis Factor Antagonist–Based Therapy for Patients With Crohn’s Disease Reduces Costs Compared With Late Initiation. Clinical Gastroenterology and Hepatology 2019;17:1515-1524.e4. [DOI: 10.1016/j.cgh.2018.07.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
3 Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-matary W, Huynh H, Jantchou P, Lawrence S, Otley A, Sherlock M, Walters T, Kappelman MD, Sadowski D, Marshall JK, Griffiths A. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Gastroenterology 2019;157:320-48. [DOI: 10.1053/j.gastro.2019.03.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
4 Zhao D, Yang B, Ye C, Zhang S, Lv X, Chen Q. Enteral nutrition ameliorates the symptoms of Crohn's disease in mice via activating special pro-resolving mediators through innate lymphoid cells. Innate Immun 2021;27:533-42. [PMID: 34791916 DOI: 10.1177/17534259211057038] [Reference Citation Analysis]
5 Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291-1302. [PMID: 28326566 DOI: 10.1111/apt.14030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 146] [Article Influence: 34.4] [Reference Citation Analysis]
6 Weisshof R, Golan MA, Yvellez OV, Rubin DT. The use of tofacitinib in the treatment of inflammatory bowel disease. Immunotherapy 2018;10:837-49. [DOI: 10.2217/imt-2018-0015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Scoville EA, Schwartz DA. Endoscopy in inflammatory bowel disease: advances in disease management. Gastrointest Endosc 2017;86:952-61. [PMID: 28886962 DOI: 10.1016/j.gie.2017.08.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Day AS. Re: American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. Transl Pediatr 2018;7:11-3. [PMID: 29441278 DOI: 10.21037/tp.2017.12.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Schultheiss JPD, Mahmoud R, Louwers JM, van der Kaaij MT, van Hellemondt BP, van Boeckel PG, Mahmmod N, Jharap B, Fidder HH, Oldenburg B. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2021;54:1298-308. [PMID: 34559428 DOI: 10.1111/apt.16605] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
10 Ho SS, Wall C, Gearry RB, Keenan J, Day AS. A Pilot Study Evaluating Novel Urinary Biomarkers for Crohn's Disease. Inflamm Intest Dis 2020;5:212-20. [PMID: 33313074 DOI: 10.1159/000510682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li Z, Kuang X, Chen T, Shen T, Wu J. Peptide YY 3-36 attenuates trinitrobenzene sulfonic acid-induced colitis in mice by modulating Th1/Th2 differentiation. Bioengineered 2022;13:10144-58. [PMID: 35443853 DOI: 10.1080/21655979.2022.2064147] [Reference Citation Analysis]
12 Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019;56:307-20. [PMID: 31088326 DOI: 10.1080/10408363.2019.1619159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
13 D'Arcangelo G, Aloi M. Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say? Paediatr Drugs 2020;22:463-72. [PMID: 32572841 DOI: 10.1007/s40272-020-00406-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Argollo M, Fiorino G, Hindryckx P, Peyrin-biroulet L, Danese S. Novel therapeutic targets for inflammatory bowel disease. Journal of Autoimmunity 2017;85:103-16. [DOI: 10.1016/j.jaut.2017.07.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 11.8] [Reference Citation Analysis]
15 Novak G, Stevens T, Van Viegen T, Bossuyt P, Štabuc B, Jeyarajah J, Zou G, Gaemers IC, Mckee TD, Fu F, Shackelton LM, Khanna R, van den Brink GR, Sandborn WJ, Feagan BG, Pai RK, Jairath V, Vande Casteele N, D’haens G. Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease. Aliment Pharmacol Ther 2019;49:1401-9. [DOI: 10.1111/apt.15250] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
16 Klang E, Barash Y, Margalit RY, Soffer S, Shimon O, Albshesh A, Ben-Horin S, Amitai MM, Eliakim R, Kopylov U. Deep learning algorithms for automated detection of Crohn's disease ulcers by video capsule endoscopy. Gastrointest Endosc 2020; 91: 606-613. e2. [PMID: 31743689 DOI: 10.1016/j.gie.2019.11.012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 15.3] [Reference Citation Analysis]
17 Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-Matary W, Huynh H, Jantchou P, Lawrence S, Otley A, Sherlock M, Walters T, Kappelman MD, Sadowski D, Marshall JK, Griffiths A. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. J Can Assoc Gastroenterol 2019;2:e35-63. [PMID: 31294379 DOI: 10.1093/jcag/gwz018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Beelen EMJ, van der Woude CJ, Pierik MJ, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Dijkstra G, Bruggink AH, Erler NS, Schouten WR, de Vries AC; Dutch Initiative on Crohn's and Colitis (ICC). Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease: A Nationwide Cohort Study. Ann Surg 2021;273:557-63. [PMID: 31188225 DOI: 10.1097/SLA.0000000000003395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
19 Macaluso FS, Maida M, Grova M, Crispino F, Teresi G, Orlando A, Orlando A. Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. Therap Adv Gastroenterol 2021;14:17562848211010668. [PMID: 33995582 DOI: 10.1177/17562848211010668] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tang J, Yang Q, Huang Z, Guo H, Chao K, Hu P, Gao X. Early serum infliximab trough level and mucosal healing could be predictors for one-year outcome after initiating therapy in Crohn's disease. Scand J Gastroenterol 2020;55:1035-40. [PMID: 32819192 DOI: 10.1080/00365521.2020.1800077] [Reference Citation Analysis]
21 Hoekman DR, Löwenberg M, van den Brink GR, Ponsioen CY, Benninga MA, D'Haens GR. A prospective study comparing patient-reported outcomes in Crohn's disease. Eur J Gastroenterol Hepatol 2020;32:38-44. [PMID: 31651651 DOI: 10.1097/MEG.0000000000001568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Varyani F, Samuel S. “Can Magnetic Resonance Enterography (MRE) replace ileo-colonoscopy for evaluating disease activity in Crohn's disease?”. Best Practice & Research Clinical Gastroenterology 2019;38-39:101621. [DOI: 10.1016/j.bpg.2019.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol 2020;14:807-17. [PMID: 32762582 DOI: 10.1080/17474124.2020.1804361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Shivashankar R, Pardi DS. Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease. Gastroenterol Clin North Am 2017;46:589-601. [PMID: 28838417 DOI: 10.1016/j.gtc.2017.05.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Xiang L, Ding X, Li Q, Wu X, Dai M, Long C, He Z, Cui B, Zhang F. Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment? MicrobBiotechnol. 2020;13:760-769. [PMID: 31958884 DOI: 10.1111/1751-7915.13536] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
26 Iacucci M, Jeffery L, Acharjee A, Nardone OM, Zardo D, Smith SCL, Bazarova A, Cannatelli R, Shivaji UN, Williams J, Gkoutos G, Ghosh S. Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission. Inflamm Bowel Dis 2021:izab059. [PMID: 34019073 DOI: 10.1093/ibd/izab059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Narula N, Wong ECL, Colombel JF, Sandborn WJ, Ferrante M, Marshall JK, Reinisch W, Dulai PS. Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease. J Crohns Colitis 2021:jjab183. [PMID: 34664635 DOI: 10.1093/ecco-jcc/jjab183] [Reference Citation Analysis]
28 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Ahmad A, Laverty AA, Alexakis C, Cowling T, Saxena S, Majeed A, Pollok RCG. Changing nationwide trends in endoscopic, medical and surgical admissions for inflammatory bowel disease: 2003-2013. BMJ Open Gastroenterol 2018;5:e000191. [PMID: 29607052 DOI: 10.1136/bmjgast-2017-000191] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
30 Zittan E, Gralnek IM, Berns MS. The New Proactive Approach and Precision Medicine in Crohn's Disease. Biomedicines 2020;8:E193. [PMID: 32635316 DOI: 10.3390/biomedicines8070193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Noor NM, Lee JC. The Endoscopic Healing Index in Crohn's Disease: A Serum Proteomic Biomarker for Monitoring Disease Activity. Inflamm Bowel Dis 2022:izac126. [PMID: 35704706 DOI: 10.1093/ibd/izac126] [Reference Citation Analysis]
32 Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24(23): 2457-2467 [PMID: 29930467 DOI: 10.3748/wjg.v24.i23.2457] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
33 Agrawal M, Colombel JF. Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat? Gastrointest Endosc Clin N Am. 2019;29:421-436. [PMID: 31078245 DOI: 10.1016/j.giec.2019.02.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
34 Halloran BP, Jamil LH, Lo SK, Reeson M, Vasiliauskas EA, Targan S, Ippoliti A, Mann NK, Melmed GY. Double-Balloon Endoscopy in Crohn Disease: A Tertiary Referral Center Experience. Inflamm Bowel Dis 2021;27:1248-55. [PMID: 33155643 DOI: 10.1093/ibd/izaa287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741-1755. [PMID: 27914655 DOI: 10.1016/s0140-6736(16)31711-1] [Cited by in Crossref: 615] [Cited by in F6Publishing: 285] [Article Influence: 102.5] [Reference Citation Analysis]
36 Arieira C, Dias de Castro F, Cúrdia Gonçalves T, Moreira MJ, Cotter J. Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine? Scandinavian Journal of Gastroenterology 2020;55:920-3. [DOI: 10.1080/00365521.2020.1792543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Chen R, Li L, Chao K, Hong M, Cao Q, Ye L, Zhou G, Fang X, Guo H, Cao X, Ye X, Zeng Z, Chen M, Zhang S. Platelet-to-lymphocyte percentage ratio index: a simple non-invasive index to monitor the endoscopic activity in Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820979442. [PMID: 33425010 DOI: 10.1177/1756284820979442] [Reference Citation Analysis]
38 Cannatelli R, Bazarova A, Zardo D, Nardone OM, Shivaji U, Smith SCL, Gkoutos G, Ricci C, Gui XS, Ghosh S, Iacucci M. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients. Inflamm Bowel Dis. 2020;. [PMID: 32592477 DOI: 10.1093/ibd/izaa163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
39 Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease.Nat Rev Dis Primers. 2020;6:22. [PMID: 32242028 DOI: 10.1038/s41572-020-0156-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 23.5] [Reference Citation Analysis]
40 Lopez RN, Day AS. The Loneliness of Long-Term Thiopurine Monotherapy for Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021;66:1390-1. [PMID: 32767152 DOI: 10.1007/s10620-020-06512-y] [Reference Citation Analysis]
41 Gallego JC, de Juan C, Echarri A, Lopez-de-ullibarri I. Small-Bowel Crohn Disease Treated With Anti–Tumor Necrosis Factor-α Therapy: MR Enterography Score Changes After 1 Year Predict Long-Term Outcomes. American Journal of Roentgenology 2019;213:1240-6. [DOI: 10.2214/ajr.19.21186] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
42 Pauwels RWM, de Vries AC, van der Woude CJ. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice. J Gastroenterol Hepatol 2020;35:1893-901. [PMID: 32291796 DOI: 10.1111/jgh.15063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Lin L, Zhou G, Chen P, Wang Y, Han J, Chen M, He Y, Zhang S. Which long noncoding RNAs and circular RNAs contribute to inflammatory bowel disease? Cell Death Dis 2020;11:456. [PMID: 32541691 DOI: 10.1038/s41419-020-2657-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
44 Snowden JA, Panés J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P, Hawkey C, Kazmi M, Lindsay JO, Onida F, Salas A, Saccardi R, Vermeire S, Rovira M, Ricart E; European Crohn’s and Colitis Organisation (ECCO)., European Society for Blood and Marrow Transplantation (EBMT)., Autoimmune Diseases Working Party (ADWP)., Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE). Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. J Crohns Colitis 2018;12:476-88. [PMID: 29325112 DOI: 10.1093/ecco-jcc/jjx184] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
45 Vetter M, Neurath M. Treatment Perspectives in Crohn’s Disease. Digestion 2018;98:135-42. [DOI: 10.1159/000488449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Chuah KH, Raja Ali RA, Hilmi IN. Decreasing major surgical rates for Crohn's disease in an emerging economy over two decades: Is it due to biologic therapy? Indian J Gastroenterol 2020;39:261-7. [PMID: 32613522 DOI: 10.1007/s12664-020-01044-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ripollés T, Poza J, Suarez Ferrer C, Martínez-Pérez MJ, Martín-Algíbez A, de Las Heras Paez B. Evaluation of Crohn's Disease Activity: Development of an Ultrasound Score in a Multicenter Study. Inflamm Bowel Dis 2021;27:145-54. [PMID: 32507880 DOI: 10.1093/ibd/izaa134] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
48 Chateau T, Peyrin-Biroulet L. Evolving therapeutic goals in Crohn's disease management. United European Gastroenterol J 2020;8:133-9. [PMID: 32213074 DOI: 10.1177/2050640619887316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
49 Bergenheim F, Seidelin JB, Pedersen MT, Mead BE, Jensen KB, Karp JM, Nielsen OH. Fluorescence-based tracing of transplanted intestinal epithelial cells using confocal laser endomicroscopy. Stem Cell Res Ther 2019;10:148. [PMID: 31133056 DOI: 10.1186/s13287-019-1246-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
50 Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol. 2020;14:335-345. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Picco MF. PiCaSSO: a predictive score for endoscopic findings in ulcerative colitis that sounds like art but is all science. Gastrointest Endosc 2017;86:1128-30. [PMID: 29146084 DOI: 10.1016/j.gie.2017.04.010] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Day AS, Leach ST, Lemberg DA. An update on diagnostic and prognostic biomarkers in inflammatory bowel disease. Expert Rev Mol Diagn. 2017;17:835-843. [PMID: 28770636 DOI: 10.1080/14737159.2017.1364160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
53 Bonnaud G, Bouhnik Y, Hagege H, Hebuterne X, Pariente B, Roblin X, Peyrin-Biroulet L. Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. Dig Liver Dis 2020;52:704-20. [PMID: 32402743 DOI: 10.1016/j.dld.2020.03.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Wong ECL, Buffone E, Lee SJ, Dulai PS, Marshall JK, Reinisch W, Narula N. End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease. J Crohns Colitis 2021;15:1114-9. [PMID: 33245751 DOI: 10.1093/ecco-jcc/jjaa242] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Fraquelli M, Castiglione F, Calabrese E, Maconi G. Impact of intestinal ultrasound on the management of patients with inflammatory bowel disease: how to apply scientific evidence to clinical practice. Dig Liver Dis 2020;52:9-18. [PMID: 31732443 DOI: 10.1016/j.dld.2019.10.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
56 Hirai F, Andoh A, Ueno F, Watanabe K, Ohmiya N, Nakase H, Kato S, Esaki M, Endo Y, Yamamoto H, Matsui T, Iida M, Hibi T, Watanabe M, Suzuki Y, Matsumoto T. Efficacy of Endoscopic Balloon Dilation for Small Bowel Strictures in Patients With Crohn's Disease: A Nationwide, Multi-centre, Open-label, Prospective Cohort Study. J Crohns Colitis. 2018;12:394-401. [PMID: 29194463 DOI: 10.1093/ecco-jcc/jjx159] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
57 Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Janneke van der Woude C, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L. Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01268-4. [PMID: 34843987 DOI: 10.1016/j.cgh.2021.11.030] [Reference Citation Analysis]
58 Zhou FS, Gao N, Sun X, Jiang XY, Chen JJ, Mao QQ, Zhong L. C-reactive protein/abumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease: A retrospective study. Medicine (Baltimore) 2021;100:e24925. [PMID: 33725853 DOI: 10.1097/MD.0000000000024925] [Reference Citation Analysis]
59 Taylor SA, Rieder F, Fletcher JG. Differences in the imaging of Crohn's disease patients between North America and Europe: are we ready to bridge the divide? Abdom Radiol (NY) 2019;44:1637-43. [PMID: 30580391 DOI: 10.1007/s00261-018-1872-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2017;15:1427-1434.e2. [PMID: 28365485 DOI: 10.1016/j.cgh.2017.03.032] [Cited by in Crossref: 138] [Cited by in F6Publishing: 121] [Article Influence: 27.6] [Reference Citation Analysis]
61 Nigam GB, Nayeemuddin S, Kontopantelis E, Hayee B, Limdi JK. UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterol 2021;12:22-9. [PMID: 33493247 DOI: 10.1136/flgastro-2019-101372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Caprioli F, Daperno M, Bravatà I, Brigido A, Frigerio D, Secchi O, Rispo A. Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. Eur J Gastroenterol Hepatol 2021;33:1082-90. [PMID: 34213505 DOI: 10.1097/MEG.0000000000002183] [Reference Citation Analysis]
63 Oliva S, Veraldi S, Cucchiara S, Russo G, Spagnoli A, Cohen SA. Assessment of a new score for capsule endoscopy in pediatric Crohn's disease (CE-CD). Endosc Int Open 2021;9:E1480-90. [PMID: 34540539 DOI: 10.1055/a-1522-8723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
64 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
65 Conklin LS, Hanley PJ, Galipeau J, Barrett J, Bollard CM. Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: Lessons from the acute graft versus host disease experience. Cytotherapy 2017;19:655-67. [PMID: 28433516 DOI: 10.1016/j.jcyt.2017.03.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
66 Yang JY, Lund JL, Pate V, Kappelman MD. Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019. Inflamm Bowel Dis 2022:izac136. [PMID: 35929644 DOI: 10.1093/ibd/izac136] [Reference Citation Analysis]
67 Fernandes SR, Rodrigues RV, Bernardo S, Cortez-pinto J, Rosa I, da Silva JP, Gonçalves AR, Valente A, Baldaia C, Santos PM, Correia L, Venâncio J, Campos P, Pereira AD, Velosa J. Transmural Healing Is Associated with Improved Long-term Outcomes of Patients with Crohnʼs Disease: . Inflammatory Bowel Diseases 2017;23:1403-9. [DOI: 10.1097/mib.0000000000001143] [Cited by in Crossref: 89] [Cited by in F6Publishing: 35] [Article Influence: 17.8] [Reference Citation Analysis]
68 Patel RN, Nigam GB, Jatale RG, Desai D, Makharia G, Ahuja V, Limdi JK. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Indian J Gastroenterol 2020;39:176-85. [PMID: 32483692 DOI: 10.1007/s12664-020-01047-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
69 Guardiola J, Lobatón T, Cerrillo E, Ferreiro-iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-moranta F. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 2018;41:514-29. [DOI: 10.1016/j.gastre.2018.05.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Gong L, Zhang YL, Sun LX, Chen GR, Wu D. Mucosal healing in intestinal Behçet's disease: A systematic review and meta-analysis. J Dig Dis 2021;22:83-90. [PMID: 33314672 DOI: 10.1111/1751-2980.12965] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Snir Y, Iacucci M. The Role of Narrowed Spectrum Technologies and Dye-based Endoscopy in Inflammatory Bowel Disease: New Advances and Opportunities. Techniques and Innovations in Gastrointestinal Endoscopy 2021;23:42-56. [DOI: 10.1016/j.tige.2020.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Bromke MA, Neubauer K, Kempiński R, Krzystek-Korpacka M. Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis. J Clin Med 2021;10:2203. [PMID: 34069684 DOI: 10.3390/jcm10102203] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Nardone OM, Snir Y, Hodson J, Cannatelli R, Labarile N, Siau K, Hassan C, Yanai H, Dotan I, Ghosh S, Iacucci M. Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2022;15:175628482210925. [DOI: 10.1177/17562848221092594] [Reference Citation Analysis]
74 Bakshi N, Hart AL, Lee MC, Williams ACC, Lackner JM, Norton C, Croft P. Chronic pain in patients with inflammatory bowel disease. Pain 2021;162:2466-71. [PMID: 34534174 DOI: 10.1097/j.pain.0000000000002304] [Reference Citation Analysis]
75 Dolan KT, Chang EB. Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases. Mol Nutr Food Res 2017;61. [PMID: 27346644 DOI: 10.1002/mnfr.201600129] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
76 Scarallo L, Lionetti P. Dietary Management in Pediatric Patients with Crohn's Disease. Nutrients 2021;13:1611. [PMID: 34064976 DOI: 10.3390/nu13051611] [Reference Citation Analysis]
77 le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022:S0016-5085(21)04067-1. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterol Hepatol 2021;44:87-95. [PMID: 32680729 DOI: 10.1016/j.gastrohep.2020.04.015] [Reference Citation Analysis]
79 Mitchel EB, Rosh JR. Pediatric Management of Crohn’s Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.013] [Reference Citation Analysis]
80 Buisson A, Hordonneau C, Goutorbe F, Allimant C, Goutte M, Reymond M, Pereira B, Bommelaer G. Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn’s disease. J Gastroenterol 2019;54:312-20. [DOI: 10.1007/s00535-018-1505-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
81 Kayal M, Plietz M, Radcliffe M, Rizvi A, Yzet C, Tixier E, Hirten RP, Cohen B, Sylla P, Khaitov S, Greenstein A, Colombel JF, Dubinsky MC, Ungaro RC. Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. Aliment Pharmacol Ther 2019;50:1189-94. [PMID: 31579976 DOI: 10.1111/apt.15505] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
82 Al Khoury A, Balram B, Bessissow T, Afif W, Gonczi L, Abreu M, Lakatos PL. Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review. Dig Dis Sci 2021. [PMID: 34021425 DOI: 10.1007/s10620-021-07025-y] [Reference Citation Analysis]
83 Guardiola J, Lobatón T, Cerrillo E, Ferreiro-iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-moranta F. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2018;41:514-29. [DOI: 10.1016/j.gastrohep.2018.05.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
84 Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:361-8. [PMID: 29210919 DOI: 10.1097/MPG.0000000000001850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
85 Minar P, Jackson K, Tsai YT, Rosen MJ, Northcutt M, Khodoun M, Finkelman FD, Denson LA. A Low Neutrophil CD64 Index Is Associated with Sustained Remission During Infliximab Maintenance Therapy. Inflamm Bowel Dis 2016;22:2641-7. [PMID: 27749455 DOI: 10.1097/MIB.0000000000000922] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
86 Kopylov U, Koulaouzidis A, Klang E, Carter D, Ben-Horin S, Eliakim R. Monitoring of small bowel Crohn's disease. Expert Rev Gastroenterol Hepatol 2017;11:1047-58. [PMID: 28737951 DOI: 10.1080/17474124.2017.1359541] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
87 Egan C, Doherty GA. Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment? Expert Opinion on Biological Therapy 2019;19:907-18. [DOI: 10.1080/14712598.2019.1615050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
88 Heriot A, Smart P. Current Status of Segmental Colectomy in Select Crohn's Disease Patients. Clin Colon Rectal Surg 2019;32:249-54. [PMID: 31275070 DOI: 10.1055/s-0039-1683906] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
89 Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”? World J Gastroenterol 2019; 25(41): 6172-6189 [PMID: 31749591 DOI: 10.3748/wjg.v25.i41.6172] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
90 Hoekman DR, Diederen K, Koot BG, Tabbers MM, Kindermann A, Benninga MA. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. Eur J Pediatr 2016;175:1335-42. [PMID: 27573259 DOI: 10.1007/s00431-016-2762-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
91 D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D; GETAID. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018;154:1343-1351.e1. [PMID: 29317275 DOI: 10.1053/j.gastro.2018.01.004] [Cited by in Crossref: 138] [Cited by in F6Publishing: 117] [Article Influence: 34.5] [Reference Citation Analysis]
92 Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis 2020;14:542-56. [PMID: 31549158 DOI: 10.1093/ecco-jcc/jjz162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
93 Shen B, Kochhar G, Navaneethan U, Liu X, Farraye FA, Gonzalez-Lama Y, Bruining D, Pardi DS, Lukas M, Bortlik M, Wu K, Sood A, Schwartz DA, Sandborn WJ;  Global Interventional Inflammatory Bowel Disease Group. Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. Gastrointest Endosc. 2019;89:215-237. [PMID: 30365985 DOI: 10.1016/j.gie.2018.09.045] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
94 Pecere S, Holleran G, Ainora ME, Garcovich M, Scaldaferri F, Gasbarrini A, Zocco MA. Usefulness of contrast-enhanced ultrasound (CEUS) in Inflammatory Bowel Disease (IBD). Digestive and Liver Disease 2018;50:761-7. [DOI: 10.1016/j.dld.2018.03.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
95 Al Khoury A, Xiao Y, Golovics PA, Kohen R, Afif W, Wild G, Friedman G, Galiatsatos P, Hilzenrat N, Szilagyi A, Wyse J, Cohen A, Bitton A, Bessissow T, Lakatos PL. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. Dig Liver Dis 2021;53:980-6. [PMID: 33640302 DOI: 10.1016/j.dld.2021.02.006] [Reference Citation Analysis]
96 Sun H, Vesely R, Lee KJ, Klein A, Ikima M, Mulberg AE. Pediatric Crohn Disease Clinical Outcome Assessments and Biomarkers: Current State and Path Forward for Global Collaboration. Journal of Pediatric Gastroenterology & Nutrition 2017;64:368-72. [DOI: 10.1097/mpg.0000000000001284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
97 Oshima S, Watanabe M. Genetic and environmental factors drive personalized medicine for Crohn's disease. J Clin Invest 2018;128:4758-60. [PMID: 30320603 DOI: 10.1172/JCI124303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
98 Sagami S, Kobayashi T, Miyatani Y, Okabayashi S, Yamazaki H, Takada T, Kinoshita K, Allocca M, Kunisaki R, Ramaswamy PK, Shiraki M, Hibi T, Kataoka Y. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:908-921.e6. [PMID: 32777549 DOI: 10.1016/j.cgh.2020.07.067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
99 Chen P, Zhou G, Lin J, Li L, Zeng Z, Chen M, Zhang S. Serum Biomarkers for Inflammatory Bowel Disease. Front Med (Lausanne). 2020;7:123. [PMID: 32391365 DOI: 10.3389/fmed.2020.00123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
100 Kourkoulis P, Michalopoulos G, Katifelis H, Giannopoulou I, Lazaris AC, Papaconstantinou I, Karamanolis G, Gazouli M. Leucine-rich alpha-2 glycoprotein 1, high mobility group box 1, matrix metalloproteinase 3 and annexin A1 as biomarkers of ulcerative colitis endoscopic and histological activity. Eur J Gastroenterol Hepatol 2020;32:1106-15. [PMID: 32483088 DOI: 10.1097/MEG.0000000000001783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
101 Scarallo L, Bolasco G, Barp J, Bianconi M, di Paola M, Di Toma M, Naldini S, Paci M, Renzo S, Labriola F, De Masi S, Alvisi P, Lionetti P. Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. Inflamm Bowel Dis 2021:izab046. [PMID: 33835155 DOI: 10.1093/ibd/izab046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Ho SSC, Keenan JI, Day AS. Parent Perspectives of Diagnostic and Monitoring Tests Undertaken by Their Child with Inflammatory Bowel Disease. Pediatr Gastroenterol Hepatol Nutr 2021;24:19-29. [PMID: 33505890 DOI: 10.5223/pghn.2021.24.1.19] [Reference Citation Analysis]
103 Moran CP, Neary B, Doherty GA. Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. World J Gastrointest Endosc 2016; 8(20): 723-732 [PMID: 28042386 DOI: 10.4253/wjge.v8.i20.723] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
104 Xiao-qing D, Xiao-ying L, Xue-jun W, Xiao-cong G, Jun-yi L, Yun-qiong L, Li L, Jia-ni C, Dan Z, Yuan L, Huan-gan W, Chen X, Xiao-peng M. Study on the regulatory effect of herbal cake-partitioned moxibustion on colonic CD206, AMPK and TSC2 in rats with Crohn disease. J Acupunct Tuina Sci 2021;19:329-37. [DOI: 10.1007/s11726-021-1263-7] [Reference Citation Analysis]
105 Ma L, Li W, Zhuang N, Yang H, Liu W, Zhou W, Jiang Y, Li J, Zhu Q, Qian J. Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn's disease. Therap Adv Gastroenterol 2021;14:17562848211016259. [PMID: 34178114 DOI: 10.1177/17562848211016259] [Reference Citation Analysis]
106 Scarallo L, Alvisi P, Bolasco G, Di Toma M, Lanari M, Cangiari A, Paci M, Naldini S, Renzo S, Barp J, De Masi S, Lionetti P. Mucosal and Histologic Healing in Children With Inflammatory Bowel Disease Treated With Antitumor Necrosis Factor-Alpha. J Pediatr Gastroenterol Nutr 2021;72:728-35. [PMID: 33399329 DOI: 10.1097/MPG.0000000000003043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Smith SCL, Banbury C, Zardo D, Cannatelli R, Nardone OM, Shivaji UN, Ghosh S, Oppenheimer PG, Iacucci M. Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease. PLoS One 2021;16:e0252210. [PMID: 34077453 DOI: 10.1371/journal.pone.0252210] [Reference Citation Analysis]
108 Battat R, Sandborn WJ. Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00383-9. [PMID: 33819666 DOI: 10.1016/j.cgh.2021.03.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
109 Brown SR, Fearnhead NS, Faiz OD, Abercrombie JF, Acheson AG, Arnott RG, Clark SK, Clifford S, Davies RJ, Davies MM, Douie WJP, Dunlop MG, Epstein JC, Evans MD, George BD, Guy RJ, Hargest R, Hawthorne AB, Hill J, Hughes GW, Limdi JK, Maxwell-Armstrong CA, O'Connell PR, Pinkney TD, Pipe J, Sagar PM, Singh B, Soop M, Terry H, Torkington J, Verjee A, Walsh CJ, Warusavitarne JH, Williams AB, Williams GL, Wilson RG; ACPGBI IBD Surgery Consensus Collaboration. The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease. Colorectal Dis. 2018;20 Suppl 8:3-117. [PMID: 30508274 DOI: 10.1111/codi.14448] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
110 Atia O, Orlanski-Meyer E, Lujan R, Ledderman N, Greenfeld S, Kariv R, Daher S, Yanai H, Loewenberg Weisband Y, Gabay H, Matz E, Nevo D, Israeli E, Schwartz D, Chowers Y, Dotan I, Turner D. Improved outcomes of pediatric and adult Crohn's disease and association with emerging use of biologics - a nationwide study from the epi-IIRN. J Crohns Colitis 2021:jjab204. [PMID: 34791083 DOI: 10.1093/ecco-jcc/jjab204] [Reference Citation Analysis]
111 Popa DE, Manea NC, Gheonea DI, PÎrlog MC. Development of a Software for Treat-To-Target Strategy Implementation and Increasing Quality of Life in Patients with Inflammatory Bowel Disease. Curr Health Sci J 2020;46:103-10. [PMID: 32874680 DOI: 10.12865/CHSJ.46.02.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Lazzerini M, Villanacci V, Pellegrin MC, Martelossi S, Magazzù G, Pellegrino S, Lucanto MC, Barabino A, Calvi A, Arrigo S, Lionetti P, Fontana M, Zuin G, Maggiore G, Bramuzzo M, Maschio M, Salemme M, Manenti S, Lorenzi L, Decorti G, Montico M, Ventura A. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. Clin Gastroenterol Hepatol 2017;15:1382-1389.e1. [PMID: 28286192 DOI: 10.1016/j.cgh.2017.02.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
113 Heier CR, Fiorillo AA, Chaisson E, Gordish-Dressman H, Hathout Y, Damsker JM, Hoffman EP, Conklin LS. Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease. Clin Transl Gastroenterol 2016;7:e192. [PMID: 27628422 DOI: 10.1038/ctg.2016.49] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
114 Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. J Can Assoc Gastroenterol 2019;2:e1-e34. [PMID: 31294378 DOI: 10.1093/jcag/gwz019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
115 Clark-Snustad KD, Singla A, Lee SD. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists. Dig Dis Sci 2019;64:1952-8. [PMID: 30815825 DOI: 10.1007/s10620-019-05490-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
116 Salem MS, Melmed GY. The Role of Histology in Determining Disease Activity, Treatment, and Prognosis: Are We There yet? Gastrointest Endosc Clin N Am 2019;29:437-46. [PMID: 31078246 DOI: 10.1016/j.giec.2019.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
117 Argollo M, Fiorino G, Peyrin-biroulet L, Danese S. Vedolizumab for the treatment of Crohn’s disease. Expert Review of Clinical Immunology 2018;14:179-89. [DOI: 10.1080/1744666x.2018.1438189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
118 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
119 Nardone OM, Cannatelli R, Zardo D, Ghosh S, Iacucci M. Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease? Therap Adv Gastroenterol 2019;12:1756284819863015. [PMID: 31360224 DOI: 10.1177/1756284819863015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
120 Alhagamhmad MH. Enteral Nutrition in the Management of Crohn's Disease: Reviewing Mechanisms of Actions and Highlighting Potential Venues for Enhancing the Efficacy. Nutr Clin Pract 2018;33:483-92. [PMID: 29323428 DOI: 10.1002/ncp.10004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
121 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Reference Citation Analysis]
122 Ripollés T, Muñoz F, Martínez-Pérez MJ, de Miguel E, Cordón JP, de la Heras Páez de la Cadena B. Usefulness of intestinal ultrasound in inflammatory bowel disease. Radiologia (Engl Ed) 2021;63:89-102. [PMID: 33189372 DOI: 10.1016/j.rx.2020.10.001] [Reference Citation Analysis]
123 Patil SA, Cross RK. Medical versus surgical management of penetrating Crohn's disease: the current situation and future perspectives. Expert Rev Gastroenterol Hepatol 2017;11:843-8. [PMID: 28633544 DOI: 10.1080/17474124.2017.1342536] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
124 Wu S, Zeng L, Li W, Wu YT, Jing JG, Zhuang H, Wang YF. The value of multi-modes of ultrasound in evaluating segmental mucosal healing in patients with Crohn's disease. Dig Liver Dis 2022:S1590-8658(21)00896-3. [PMID: 34991975 DOI: 10.1016/j.dld.2021.12.009] [Reference Citation Analysis]
125 Kim KO. Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice. Clin Endosc 2022;55:480-8. [PMID: 35898147 DOI: 10.5946/ce.2022.108] [Reference Citation Analysis]
126 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
127 Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:580-6. [PMID: 30165638 DOI: 10.1093/ibd/izy272] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 15.5] [Reference Citation Analysis]
128 Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. J Crohns Colitis 2021;15:462-70. [PMID: 32931556 DOI: 10.1093/ecco-jcc/jjaa189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, Tapete G, Costa F. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol 2018; 24(33): 3681-3694 [PMID: 30197475 DOI: 10.3748/wjg.v24.i33.3681] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 70] [Article Influence: 22.0] [Reference Citation Analysis]
130 Klang E, Amitai MM, Lahat A, Yablecovitch D, Avidan B, Neuman S, Levhar N, Rozendorn N, Weiss B, Ben-Horin S, Eliakim R, Kopylov U, Israeli IBD research Nucleus [IIRN). Capsule Endoscopy Validation of the Magnetic Enterography Global Score in Patients with Established Crohn's Disease. J Crohns Colitis. 2018;12:313-320. [PMID: 29182750 DOI: 10.1093/ecco-jcc/jjx156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
131 Alfarone L, Dal Buono A, Craviotto V, Zilli A, Fiorino G, Furfaro F, D'Amico F, Danese S, Allocca M. Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows. J Clin Med 2022;11:353. [PMID: 35054047 DOI: 10.3390/jcm11020353] [Reference Citation Analysis]
132 Ballester Ferré MP, Boscá-Watts MM, Mínguez Pérez M. Crohn's disease. Med Clin (Barc) 2018;151:26-33. [PMID: 29246562 DOI: 10.1016/j.medcli.2017.10.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
133 Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology 2020;159:139-47. [PMID: 32224129 DOI: 10.1053/j.gastro.2020.03.039] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 14.5] [Reference Citation Analysis]
134 Castiglione F, Imperatore N, Testa A, De Palma GD, Nardone OM, Pellegrini L, Caporaso N, Rispo A. One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing. Aliment Pharmacol Ther 2019;49:1026-39. [DOI: 10.1111/apt.15190] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 19.0] [Reference Citation Analysis]
135 McCann RK, Smith K, Gaya DR. A prospective single centre pilot evaluation of a serum calprotectin assay in unselected GI patients. Clin Biochem 2017;50:533-6. [PMID: 28093196 DOI: 10.1016/j.clinbiochem.2017.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
136 Yu YR, Rodriguez JR. Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349-355. [PMID: 29126502 DOI: 10.1053/j.sempedsurg.2017.10.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
137 Serban ED. Treat-to-target in Crohn’s disease: Will transmural healing become a therapeutic endpoint? World J Clin Cases 2018; 6(12): 501-513 [PMID: 30397606 DOI: 10.12998/wjcc.v6.i12.501] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
138 Buisson A, Mak WY, Andersen MJ, Lei D, Kahn SA, Pekow J, Cohen RD, Zmeter N, Pereira B, Rubin DT. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019;13:1012-1024. [PMID: 30726887 DOI: 10.1093/ecco-jcc/jjz023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
139 White JR, Jairath V, Moran GW. Evolution of treatment targets in Crohn's disease. Best Pract Res Clin Gastroenterol 2019;38-39:101599. [PMID: 31327410 DOI: 10.1016/j.bpg.2019.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Dig Endosc 2021;33:1008-23. [PMID: 33020947 DOI: 10.1111/den.13863] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 45.0] [Reference Citation Analysis]
142 Sævik F, Gilja OH, Nylund K. Gastrointestinal Ultrasound Can Predict Endoscopic Activity in Crohn's Disease. Ultraschall Med 2022;43:82-9. [PMID: 32330994 DOI: 10.1055/a-1149-9092] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Melek J, Štanclová M, Dědek P, Malý J, Bayer M, Pozler O, Bureš J. Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease. J Dig Dis 2020;21:705-10. [PMID: 32755026 DOI: 10.1111/1751-2980.12927] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Yablecovitch D, Lahat A, Neuman S, Levhar N, Avidan B, Ben-Horin S, Eliakim R, Kopylov U. The Lewis score or the capsule endoscopy Crohn's disease activity index: which one is better for the assessment of small bowel inflammation in established Crohn's disease? Therap Adv Gastroenterol. 2018;11:1756283X17747780. [PMID: 29399042 DOI: 10.1177/1756283x17747780] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
145 Freitas M, de Castro FD, Macedo Silva V, Arieira C, Cúrdia Gonçalves T, Leite S, Moreira MJ, Cotter J. Ultrasonographic scores for ileal Crohn's disease assessment: Better, worse or the same as contrast-enhanced ultrasound? BMC Gastroenterol 2022;22:252. [PMID: 35585503 DOI: 10.1186/s12876-022-02326-6] [Reference Citation Analysis]
146 Yao JY, Zhang M, Wang W, Peng X, Zhao JZ, Liu T, Li ZW, Sun HT, Hu P, Zhi M. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study. BMC Gastroenterol 2021;21:380. [PMID: 34663208 DOI: 10.1186/s12876-021-01946-8] [Reference Citation Analysis]
147 Cazzato G, Colagrande A, Andriola V, Lettini T, Cicco S, Candance PMV, Resta L, Vincenti L, Ingravallo G. Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives. Diagnostics (Basel) 2021;11:1570. [PMID: 34573912 DOI: 10.3390/diagnostics11091570] [Reference Citation Analysis]
148 Sengupta N, Tapper EB, Feuerstein JD. Early Versus Delayed Colonoscopy in Hospitalized Patients With Lower Gastrointestinal Bleeding: A Meta-Analysis. J Clin Gastroenterol. 2017;51:352-359. [PMID: 27466163 DOI: 10.1097/mcg.0000000000000602] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 5.6] [Reference Citation Analysis]
149 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
150 Hibiya S, Ohtsuka K, Takenaka K, Kawamoto A, Matsuyama Y, Udagawa Y, Motobayashi M, Shimizu H, Fujii T, Saito E, Nagahori M, Okamoto R, Watanabe M. Mucosal healing of small intestinal stricture is associated with improved prognosis post-dilation in Crohn's disease. BMC Gastroenterol 2022;22:218. [PMID: 35508963 DOI: 10.1186/s12876-022-02300-2] [Reference Citation Analysis]
151 Thierry ML, Rousseau H, Pouillon L, Girard-Gavanier M, Baumann C, Lopez A, Danese S, Laurent V, Peyrin-Biroulet L. Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. J Crohns Colitis. 2018;12:1180-1190. [PMID: 29985999 DOI: 10.1093/ecco-jcc/jjy098] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
152 Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. Am J Gastroenterol 2020;115:1236-45. [PMID: 32759621 DOI: 10.14309/ajg.0000000000000617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
153 Dai C, Jiang M, Sun MJ. Letter: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther 2016;43:1346. [PMID: 27166987 DOI: 10.1111/apt.13627] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
154 Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease. Clinical Gastroenterology and Hepatology 2019;17:1680-713. [DOI: 10.1016/j.cgh.2019.02.043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
155 Shah SC, Colombel JF, Sands BE, Narula N. Letter: mucosal healing is associated with improved long-term outcomes in Crohn's disease - authors' reply. Aliment Pharmacol Ther 2016;43:1347-8. [PMID: 27166988 DOI: 10.1111/apt.13637] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
156 Reinisch W, Colombel JF, D'Haens G, Sandborn WJ, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R. Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. J Crohns Colitis 2017;11:425-34. [PMID: 27815351 DOI: 10.1093/ecco-jcc/jjw178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
157 Holmer AK, Boland BS, Singh S, Neill J, Le H, Miralles A, Collins AE, Sandborn WJ, Dulai PS. A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. Inflamm Bowel Dis 2022:izac117. [PMID: 35704691 DOI: 10.1093/ibd/izac117] [Reference Citation Analysis]
158 Dal Buono A, Gabbiadini R, Furfaro F, Argollo M, Trigo TVT, Repici A, Roda G. Endoscopic Surveillance in Inflammatory Bowel Diseases: Selecting a Suitable Technology. Front Med 2022;9:855652. [DOI: 10.3389/fmed.2022.855652] [Reference Citation Analysis]
159 Gutiérrez A, Rodríguez-Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne) 2021;8:640813. [PMID: 33585530 DOI: 10.3389/fmed.2021.640813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Review of Clinical Pharmacology 2017;10:595-607. [DOI: 10.1080/17512433.2017.1318062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
161 D'Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology 2020; 158: 515-526. e10. [PMID: 31711925 DOI: 10.1053/j.gastro.2019.10.034] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
162 Hoekman DR, Stibbe JA, Baert FJ, Caenepeel P, Vergauwe P, De Vos M, Hommes DW, Benninga MA, Vermeire SA, D'Haens GR; BIRD (Belgian Inflammatory Bowel Disease Research and Development) Group; North-Holland Gut Club. Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease. J Crohns Colitis. 2018;12:517-524. [PMID: 29401297 DOI: 10.1093/ecco-jcc/jjy014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
163 Sævik F, Eriksen R, Eide GE, Gilja OH, Nylund K. Development and Validation of a Simple Ultrasound Activity Score for Crohn's Disease. J Crohns Colitis 2021;15:115-24. [PMID: 32504533 DOI: 10.1093/ecco-jcc/jjaa112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
164 Raine T, Pavey H, Qian W, Moran GW, Subramanian S, Swaby L, Travis SP, Din S, Irving PM, Lindsay JO, Parkes M, Kennedy NA. Establishment of a validated central reading system for ileocolonoscopy in an academic setting. Gut 2022;71:661-4. [PMID: 35022265 DOI: 10.1136/gutjnl-2021-325575] [Reference Citation Analysis]
165 Iacucci M, Smith SCL, Bazarova A, Shivaji UN, Bhandari P, Cannatelli R, Daperno M, Ferraz J, Goetz M, Gui X, Hayee B, De Hertogh G, Lazarev M, Li J, Nardone OM, Parra-Blanco A, Pastorelli L, Panaccione R, Occhipinti V, Rath T, Tontini GE, Vieth M, Villanacci V, Zardo D, Bisschops R, Kiesslich R, Ghosh S. An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis. Gastroenterology 2021;160:1558-1569.e8. [PMID: 33347880 DOI: 10.1053/j.gastro.2020.12.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
166 Villablanca EJ, Selin K, Hedin CRH. Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? Nat Rev Gastroenterol Hepatol 2022. [PMID: 35440774 DOI: 10.1038/s41575-022-00604-y] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
167 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Reference Citation Analysis]
168 Song K, Wu D. Shared decision-making in the management of patients with inflammatory bowel disease. World J Gastroenterol 2022; 28(26): 3092-3100 [DOI: 10.3748/wjg.v28.i26.3092] [Reference Citation Analysis]
169 Nguyen GC, Boland K, Afif W, Bressler B, Jones JL, Weizman AV, Fowler S, Halder S, Huang VW, Kaplan GG, Khanna R, Murthy SK, Ruel J, Seow CH, Targownik LE, Chawla T, Guimaraes L, Fernandes A, Saleh S, Melmed GY. Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:858-65. [PMID: 28509817 DOI: 10.1097/MIB.0000000000001152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
170 Nagata Y, Esaki M, Moriyama T, Hirano A, Umeno J, Maehata Y, Torisu T, Matsumoto T, Kitazono T. Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn's disease of inflammatory type. J Gastroenterol 2019;54:330-8. [PMID: 30244398 DOI: 10.1007/s00535-018-1511-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
171 Helwig U, Fischer I, Hammer L, Kolterer S, Rath S, Maaser C, Kucharzik T. Transmural Response and Transmural Healing Defined by Intestinal Ultrasound - New Potential Therapeutic Targets? J Crohns Colitis 2021:jjab106. [PMID: 34185843 DOI: 10.1093/ecco-jcc/jjab106] [Reference Citation Analysis]
172 Grover Z, Burgess C, Muir R, Reilly C, Lewindon PJ. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn’s disease. ECCOJC 2016;10:1159-64. [DOI: 10.1093/ecco-jcc/jjw075] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
173 D'Haens GR, Sandborn WJ, Loftus EV Jr, Hanauer SB, Schreiber S, Peyrin-Biroulet L, Panaccione R, Panés J, Baert F, Colombel JF, Ferrante M, Louis E, Armuzzi A, Zhou Q, Goteti VS, Mostafa NM, Doan TT, Petersson J, Finney-Hayward T, Song AP, Robinson AM, Danese S. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology 2022;162:1876-90. [PMID: 35122766 DOI: 10.1053/j.gastro.2022.01.044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]